. Table 1 depicts baseline characteristics. Median follow-up was 2.8 years (range 1 to 1,471 days). Table 2 shows the main results of univariate and multivariate analyses. Additionally, BMI categories had similar adjusted risk of cancer death (n ϭ 83), CHF hospitalization (n ϭ 585), and number of CHF hospitalizations (n ϭ 916) and CHF hospitalization days (n ϭ 8,646). One-week mortality was comparable among BMI categories (1.8% to 2.5%). The BMI category was independently (p ϭ 0.018) related to the number of AMIs (n ϭ 975)-adjusted relative frequency compared with normal-weight: underweight, 0.93; overweight, 0.78; obese, 0.82.
In univariate analysis, there was a significant association between BMI category and MSDD%: underweight, 68.55; normal weight, 70.24; overweight, 74.13; obese, 76.91. In univariate analysis, a higher MSDD% was significantly protective of all end points (p Ͻ 0.0001), except cancer death. However, the addition of MSDD% to the multivariate analyses did not attenuate the independent associations shown in Table 2 . AMI ϭ acute myocardial infarction; BMI ϭ body mass index; CHF ϭ chronic heart failure; HDL ϭ high-density lipoprotein cholesterol; LDL ϭ low-density lipoprotein cholesterol.
After complicated AMI, compared with normal-weight patients, overweight/obese patients did not show a higher risk of mortality or recurrent AMI or CHF hospitalization. On the contrary, in univariate analysis, being overweight/obese was associated with lower risk of mortality and recurrent AMI, and the lower risk of recurrent AMI in obese patients remained significant in multivariate analysis. Underweight patients had 52% higher adjusted mortality risk than normal-weight patients. Being overweight or obese, compared with being underweight, was independently predictive of more than 50% better survival (results not shown).
The results may seem remarkable considering the vast range of comorbidity associated with obesity, including CAD. Obesity may confer excess risk by producing an inflammatory state, promoting thrombosis and activating the sympathetic nervous system and the renin-angiotensin system (4, 5) . Because obesity increases the risk of CAD and mortality in the population (1,2,6), it might be anticipated that obesity also increases mortality in patients with AMI. Nevertheless, our results are supported by previous studies in patients undergoing percutaneous coronary intervention/cardiac surgery; the risk of mortality and cardiovascular events was decreased in obese patients and/or increased in underweight patients (7, 8) . However, in patients with CAD, elevated BMI was associated with increased risk of acute coronary events (9) . Previous results in patients after AMI are contradictory; obesity was associated with increased risk of recurrent coronary events during three years of follow-up in one study (5) , but with lower one-year mortality in another (10) . Conversely, obesity independently predicted in-hospital death in older, but not in younger, patients (10).
The reasons for the findings of the present study are probably multifactorial. Overweight/obese patients may have better tolerance to afterload-reducing medication, which may lead to ingestion of higher doses of renin-angiotensin system inhibitors and improved survival (11) . In the present study, MSDD% increased with increasing BMI, which may partly explain our findings. Another possible explanation is related to the fact that neurohormonal activation may be important to the increased cardiovascular risk associated with obesity (4). In our study, much of the negative effects of obesity might have been attenuated by the treatment given; all patients received renin-angiotensin system inhibition and 75% had beta-blockade. Consequently, any beneficial effects associated with being overweight/obese might have come into play, such as a higher metabolic reserve, providing better resistance against the metabolic stress associated with heart failure (12) . Variations in the use of neurohormonal blockers also might possibly explain different study results concerning the impact of BMI in patients with CAD (5,7-10).
Our observation that underweight patients had the worst prognosis is supported by studies in patients with CAD (7, 8) and CHF (12, 13) . Cachectic patients with CHF demonstrate multiple alterations in physiologic, biochemical, and neurohormonal pathways, leading to hemodynamic, immunologic, endocrine, metabolic, and muscular abnormalities (14) . Perhaps, after complicated AMI, lean patients may have similar deleterious abnormalities.
One may argue that our results were skewed by the younger age in overweight/obese patients. Indeed, when excluding age from the multivariate analyses, overweight and obese patients had significantly lower risk of death and recurrent AMI, and overweight patients also had lower risk of cardiac death (data not shown). Thus, age seems to be the major factor explaining why being overweight or obese was not independently protective of mortality compared with being at a normal weight. However, despite adjustment for age and numerous other variables, the adjusted mortality risk of being overweight or obese was still not higher compared with being at a normal weight but was rather lower, although not statistically significant. 
Increased Skeletal Muscle Amino Acid Release With Light Exercise in Deconditioned Patients With Heart Failure
To the Editor: The existence of muscle metabolic alterations in patients with chronic heart failure (CHF) (1) led us to test the hypothesis that even a light exercise mimicking a daily life activity (2) in CHF may induce an excess of muscle amino acid release. We focused in particular on phenylalanine (Phe) release because this amino acid is neither synthesized nor degraded within muscle (3). Twenty untrained, clinically stable, normonourished fasting male patients (Table 1 ) with moderate to severe CHF at morning underwent hemodynamic procedures to measure femoral blood flow, arterial and venous amino acid concentrations (branched chain amino acids [BCAAs: valine, leucine, isoleucine], histidine, alanine, glutamic acid, glutamine, and taurine), as well as pH and lactate and free fatty acid (FFA) levels both at baseline and at 20 W bicycle exercise oxygen consumption (VO 2 , ml·kg Ϫ1 ·min Ϫ1 ) steady state.
The net uptake and/or release of muscle amino acids was calculated as: Net balance ϭ ([A] Ϫ [V]) ϫ F where A Ϫ V is the femoral arteriovenous difference in amino acid concentrations and F is leg blood flow. Thus, a net muscle uptake means amino acid utilization, whereas a net muscle release indicates increased protein breakdown and/or amino acid alteration.
At rest, controls and CHF had similar arterial amino acid concentrations (unpaired t test). Net muscle uptake and/or release of amino acids by controls and CHF, at rest and during exercise, are illustrated in Figure 1 . At rest, CHF took up all amino acids except taurine, which was released, whereas controls released amino acids with the exception of glutamic acid and taurine, which were taken up. During exercise, CHF, but not controls, released significant amounts of Phe (from 38.2 Ϯ 2.4 to Ϫ42.3 Ϯ 3.2 mol·l Ϫ1 ·min
Ϫ1
; p Ͻ 0.01), the three BCAAs; histidine, alanine (p Ͻ 0.05 in all cases), and glutamine (p Ͻ 0.01). The uptake of glutamic acid declined (p Ͻ 0.01) and taurine was taken up (p Ͻ 0.01), resulting in levels higher than in controls (p Ͻ 0.05) (paired t test).
At rest, arterial FFA concentration as well as FFA release was higher in CHF than in controls (p Ͻ 0.05 and Ͻ0.001, respectively). During exercise the difference in FFA release between CHF and controls declined but remained significant (p Ͻ 0.01). At rest, blood femoral vein was acidotic in CHF (pH ϭ 7.34 Ϯ 0.02 vs. 7.41 Ϯ 0.01 in controls; p Ͻ 0.05); during the effort, the pH of CHF further decreased (7.31 Ϯ 0.01; p Ͻ 0.01).
This investigation shows that patients with CHF exercising at a light workload have a net muscle release of both Phe and other amino acids. The mechanisms responsible for the net release of Phe during exercise in CHF patients may include alterations in intermediary and energy metabolism within muscle cells, intracellular acidosis, and cytokine production. Indeed, the low intramuscular glycogen concentration in resting CHF patients (4) may make muscle energy metabolism more dependent on alternative substrates such as amino acids derived from cellular-free pool Values are expressed as mean Ϯ SEM. Statistical analysis: unpaired t test controls vs. patients. *p Ͻ 0.01. ACE ϭ angiotensin-converting enzyme; CHF ϭ congestive heart failure; NYHA ϭ New York Heart Association.
